Micky Daniel Tortorella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Micky Daniel Tortorella has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Gang Li
Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, PR China
8 shared publications - Lu Feng
Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong SAR, China
7 shared publications Zhengmeng Yang
Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong SAR, China
5 shared publicationsNan Hou
Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong SAR, China
4 shared publicationsShanshan Bai
Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong SAR, China
4 shared publicationsXuan Lu
Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, Hong Kong SAR, China
4 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 60, 101174
Cysteine metabolism dysregulation promotes ferroptosis in osteoarthritis: Insights from multi-species bioinformatics and experimental validation
- 10 July 2026
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 60, 101174
Open AccessCysteine metabolism dysregulation promotes ferroptosis in osteoarthritis: Insights from multi-species bioinformatics and experimental validation
- Open Access
- 14 May 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (2) , 40
Synthesis and Biological Evaluation of Thiazolyl-Benzene/Camphor Sulfonamide Derivatives as Antibacterial, Antioxidant, and Antidiabetic Compounds
Thiazolyl-benzene/camphor sulfonamide derivatives (series 4a–k, 5a–j and 6a–i) were synthesized by reaction of various aryl sulfonyl chlorides and camphor sulfonyl chlorides with 2-amino-4-phenylthiazole. The compounds were evaluated for antibacterial, antioxidant, and α-glucosidase/α-amylase inhibitory activities. Biological screening showed that 4h, 5g and 5i displayed significant activity against most Gram-positive bacteria (MICs 4.68–18.75 µg/mL), while 4b and 5i were active against most Gram-negative bacteria with similar MIC ranges. In the DPPH assay, 4e, 4f, 4g and 4h exhibited slightly stronger radical-scavenging activity than ascorbic acid (IC50 ≈ 3.5–3.8 µM vs. 4.14 µM); 5f emerged as the best dual carbohydrate-digesting enzyme inhibitor, and 5b and 5e demonstrated selectivity toward α-amylase.
- 14 May 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (2) , 40
Open AccessSynthesis and Biological Evaluation of Thiazolyl-Benzene/Camphor Sulfonamide Derivatives as Antibacterial, Antioxidant, and Antidiabetic Compounds
Thiazolyl-benzene/camphor sulfonamide derivatives (series 4a–k, 5a–j and 6a–i) were synthesized by reaction of various aryl sulfonyl chlorides and camphor sulfonyl chlorides with 2-amino-4-phenylthiazole. The compounds were evaluated for antibacterial, antioxidant, and α-glucosidase/α-amylase inhibitory activities. Biological screening showed that 4h, 5g and 5i displayed significant activity against most Gram-positive bacteria (MICs 4.68–18.75 µg/mL), while 4b and 5i were active against most Gram-negative bacteria with similar MIC ranges. In the DPPH assay, 4e, 4f, 4g and 4h exhibited slightly stronger radical-scavenging activity than ascorbic acid (IC50 ≈ 3.5–3.8 µM vs. 4.14 µM); 5f emerged as the best dual carbohydrate-digesting enzyme inhibitor, and 5b and 5e demonstrated selectivity toward α-amylase.
- Open Access
- 14 February 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
Entorhinal Cholecystokinin in Alzheimer’s Disease: Its Earliest Vulnerability and Rescue Effects Across Different Disease Stages in a Mouse Model
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline. The entorhinal cortex (Ent) is among the earliest affected regions, and its neuropeptide cholecystokinin (CCK) supports neocortical-associated memory. Although our previous work demonstrated that CCK treatment rescues cognition and neuroplasticity in aged AD mice, the correlations among CCK expression, synaptic function, and cognitive decline with aging remain poorly understood. Using 3xTg-AD mice (2–18 months), we performed stereological, histological, and molecular analyses to evaluate brain atrophy, neuronal loss, glial responses, and gene expression. Cognitive function was assessed using the novel object recognition test (NOR), motor learning was evaluated using the rotarod test, and synaptic integrity was measured via electrophysiological recordings. We also investigated the therapeutic potential of CCK-B receptor (CCK-BR) agonists on learning and memory and neuroplasticity across disease stages of AD. In 3xTg-AD mice, the Ent exhibits significant atrophy and excitatory neuronal loss as early as 7 months of age, confirming its role as one of the earliest and most severely affected regions in AD. CCK was downregulated earlier than other synaptic genes in the Ent and other brain regions. Cholecystokinin tetrapeptide (CCK-4) treatment rescued deficits in synaptic plasticity, cognition, and motor learning in 3xTg-AD mice across multiple disease stages. Long-term administration of HT-267, a CCK-BR agonist with a prolonged half-life, in young 3xTg-AD mice delayed cognitive decline, enhanced synaptic scaffolding, and restored long-term potentiation in both the cortex and hippocampus (HPC). Our findings identify CCK downregulation as an early biomarker in AD and demonstrate the therapeutic effects of CCK-BR agonists in mitigating cognitive and synaptic deficits from mild to severe disease stages. The ability of long-term CCK-4 analogue treatment to decelerate AD progression indicates its promise as an early intervention strategy. Graphical Abstract
- 14 February 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
Open AccessEntorhinal Cholecystokinin in Alzheimer’s Disease: Its Earliest Vulnerability and Rescue Effects Across Different Disease Stages in a Mouse Model
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline. The entorhinal cortex (Ent) is among the earliest affected regions, and its neuropeptide cholecystokinin (CCK) supports neocortical-associated memory. Although our previous work demonstrated that CCK treatment rescues cognition and neuroplasticity in aged AD mice, the correlations among CCK expression, synaptic function, and cognitive decline with aging remain poorly understood. Using 3xTg-AD mice (2–18 months), we performed stereological, histological, and molecular analyses to evaluate brain atrophy, neuronal loss, glial responses, and gene expression. Cognitive function was assessed using the novel object recognition test (NOR), motor learning was evaluated using the rotarod test, and synaptic integrity was measured via electrophysiological recordings. We also investigated the therapeutic potential of CCK-B receptor (CCK-BR) agonists on learning and memory and neuroplasticity across disease stages of AD. In 3xTg-AD mice, the Ent exhibits significant atrophy and excitatory neuronal loss as early as 7 months of age, confirming its role as one of the earliest and most severely affected regions in AD. CCK was downregulated earlier than other synaptic genes in the Ent and other brain regions. Cholecystokinin tetrapeptide (CCK-4) treatment rescued deficits in synaptic plasticity, cognition, and motor learning in 3xTg-AD mice across multiple disease stages. Long-term administration of HT-267, a CCK-BR agonist with a prolonged half-life, in young 3xTg-AD mice delayed cognitive decline, enhanced synaptic scaffolding, and restored long-term potentiation in both the cortex and hippocampus (HPC). Our findings identify CCK downregulation as an early biomarker in AD and demonstrate the therapeutic effects of CCK-BR agonists in mitigating cognitive and synaptic deficits from mild to severe disease stages. The ability of long-term CCK-4 analogue treatment to decelerate AD progression indicates its promise as an early intervention strategy. Graphical Abstract
- Open Access
- 19 January 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (1) , 11
Synthesis, Antimicrobial and Antiproliferative Activity of 1-Trifluoromethylphenyl-3-(4-arylthiazol-2-yl)thioureas
This study reports the exclusive and rapid synthesis of twenty-four derivatives of 1-((mono/bis)trifluoromethyl)phenyl-3-(4-arylthiazol-2-yl)thioureas (series 7, 9 and 11), along with their antimicrobial activities against Candida albicans, Mycobacterium smegmatis and seven additional bacterial strains. The anticancer potential of these compounds was evaluated against various human cancer cell lines, including A549 (lung adenocarcinoma), HeLa (cervical carcinoma), IMR32 (neuroblastoma), MCF-7 (breast adenocarcinoma), HCT116 (colon cancer) and DU145 (prostate cancer). Among these, 1-(3,5-bistrifluoromethylphenyl)-3-(thiazol-2-yl)thiourea (7i) and 1-(4-trifluoromethylphenyl)-3-(4-(3-chlorophenyl)thiazol-2-yl)thiourea (11h) demonstrated significant antimicrobial activity against M. luteus, S. aureus, S. aureus 1 and C. albicans. Additionally, 1-(4-(3-chlorophenyl)thiazol-2-yl)-3-(3-trifluoromethylphenyl)thiourea (9g) and 1-(4-trifluoromethylphenyl)-3-(4-(2-fluorophenyl)thiazol-2-yl)thiourea (11g) showed activity against Mycobacterium smegmatis. The bioassay tests indicated that many of the thiourea derivatives exhibited moderate activity against the A549, HeLa, MCF-7 and HCT116 cancer cell lines.
- 19 January 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (1) , 11
Open AccessSynthesis, Antimicrobial and Antiproliferative Activity of 1-Trifluoromethylphenyl-3-(4-arylthiazol-2-yl)thioureas
This study reports the exclusive and rapid synthesis of twenty-four derivatives of 1-((mono/bis)trifluoromethyl)phenyl-3-(4-arylthiazol-2-yl)thioureas (series 7, 9 and 11), along with their antimicrobial activities against Candida albicans, Mycobacterium smegmatis and seven additional bacterial strains. The anticancer potential of these compounds was evaluated against various human cancer cell lines, including A549 (lung adenocarcinoma), HeLa (cervical carcinoma), IMR32 (neuroblastoma), MCF-7 (breast adenocarcinoma), HCT116 (colon cancer) and DU145 (prostate cancer). Among these, 1-(3,5-bistrifluoromethylphenyl)-3-(thiazol-2-yl)thiourea (7i) and 1-(4-trifluoromethylphenyl)-3-(4-(3-chlorophenyl)thiazol-2-yl)thiourea (11h) demonstrated significant antimicrobial activity against M. luteus, S. aureus, S. aureus 1 and C. albicans. Additionally, 1-(4-(3-chlorophenyl)thiazol-2-yl)-3-(3-trifluoromethylphenyl)thiourea (9g) and 1-(4-trifluoromethylphenyl)-3-(4-(2-fluorophenyl)thiazol-2-yl)thiourea (11g) showed activity against Mycobacterium smegmatis. The bioassay tests indicated that many of the thiourea derivatives exhibited moderate activity against the A549, HeLa, MCF-7 and HCT116 cancer cell lines.
- Open Access
- 1 January 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (1) , 101754
MiR-378 mediates the ovariectomy induced bone loss via exaggerating osteoclastogenesis and transforming growth factor beta impaired osteogenesis
Osteoporosis (OP) is a disease characterized by decreased bone mass and damaged architectures. The promising treatment strategy for OP is to inhibit bone resorption while promoting bone formation. MicroRNAs (miRNAs) have been shown to be associated with osteoclastogenesis and osteogenesis processes in OP. In our previous study, we discovered that miR-378 inhibits bone marrow mesenchymal stem cell (BMSC) osteogenesis and bone formation during fracture healing. However, the role of miR-378 during OP progression is not validated. In this study, we found that miR-378 transgenic (Tg) mice exhibited excessive bone loss after ovariectomy (OVX) treatment. MiR-378 increased BMSC’s osteoclastogenesis by activating both canonical and non-canonical nuclear factor kappa-light-chain-enhancer of activated B (NFκB) signaling pathway. Tumor necrosis factor receptor-associated factor 3 (Traf3) was directly regulated by miR-378 during osteoclast differentiation. miR-378 also aggravated transforming growth factor beta (TGFβ) impaired osteogenesis upon OVX treatment. Traf3 was involved in this process as well. In in vivo study, the intravenous injection of anti-miR-378 lentivirus could significantly rescue OVX induced bone loss and bone microarchitecture impairment. This study uncovered the novel role of miR-378 in OVX induced osteoporosis. The potential of developing miRNA-378 inhibitors as novel diagnostics or blockers as therapeutics for osteoporosis is worth exploring.
- 1 January 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (1) , 101754
Open AccessMiR-378 mediates the ovariectomy induced bone loss via exaggerating osteoclastogenesis and transforming growth factor beta impaired osteogenesis
Osteoporosis (OP) is a disease characterized by decreased bone mass and damaged architectures. The promising treatment strategy for OP is to inhibit bone resorption while promoting bone formation. MicroRNAs (miRNAs) have been shown to be associated with osteoclastogenesis and osteogenesis processes in OP. In our previous study, we discovered that miR-378 inhibits bone marrow mesenchymal stem cell (BMSC) osteogenesis and bone formation during fracture healing. However, the role of miR-378 during OP progression is not validated. In this study, we found that miR-378 transgenic (Tg) mice exhibited excessive bone loss after ovariectomy (OVX) treatment. MiR-378 increased BMSC’s osteoclastogenesis by activating both canonical and non-canonical nuclear factor kappa-light-chain-enhancer of activated B (NFκB) signaling pathway. Tumor necrosis factor receptor-associated factor 3 (Traf3) was directly regulated by miR-378 during osteoclast differentiation. miR-378 also aggravated transforming growth factor beta (TGFβ) impaired osteogenesis upon OVX treatment. Traf3 was involved in this process as well. In in vivo study, the intravenous injection of anti-miR-378 lentivirus could significantly rescue OVX induced bone loss and bone microarchitecture impairment. This study uncovered the novel role of miR-378 in OVX induced osteoporosis. The potential of developing miRNA-378 inhibitors as novel diagnostics or blockers as therapeutics for osteoporosis is worth exploring.
- Open Access
- 20 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Cryo-EM structure of TMEM164 reveals distinct phospholipid remodeling mechanisms with anti-ferroptotic potential
Phospholipids in cell membrane provide both regulatory and structural function of a cell. How lipid remodeling regulates cell fate remains less explored. Here we report the cryo-electron microscopy structure of TMEM164 identified by genome-wide CRISPR screen as an anti-ferroptotic factor. The overall architecture reveals a dimer of two 7 transmembrane domain monomers and a metal ion catalytic center with phospholipid substrate in a distinct polyunsaturated fatty acyl (PUFA)-C123 intermediate state. Both loss and gain of its function result in the decline of PUFA-ePE and elevation of C16/18:1-ePE, consequently confer resistance to GPX4 inhibitor RSL3 induced ferroptosis. Mutagenesis studies further validate critical residues for the catalytic center (C123) and the chelates center (E106, Y177 and H181). Through virtual screen and rational design, we identify and test candidate inhibitors for TMEM164, including activity for Montelukast S-enantiomer with 4 order of magnitude higher affinity. Our works not only demonstrates TMEM164 as a membrane lipid remodeler that controls the ferroptotic fate, but also highlights the power of integrating multi-scale platforms to unravel distinct mechanisms and functions.
- 20 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessCryo-EM structure of TMEM164 reveals distinct phospholipid remodeling mechanisms with anti-ferroptotic potential
Phospholipids in cell membrane provide both regulatory and structural function of a cell. How lipid remodeling regulates cell fate remains less explored. Here we report the cryo-electron microscopy structure of TMEM164 identified by genome-wide CRISPR screen as an anti-ferroptotic factor. The overall architecture reveals a dimer of two 7 transmembrane domain monomers and a metal ion catalytic center with phospholipid substrate in a distinct polyunsaturated fatty acyl (PUFA)-C123 intermediate state. Both loss and gain of its function result in the decline of PUFA-ePE and elevation of C16/18:1-ePE, consequently confer resistance to GPX4 inhibitor RSL3 induced ferroptosis. Mutagenesis studies further validate critical residues for the catalytic center (C123) and the chelates center (E106, Y177 and H181). Through virtual screen and rational design, we identify and test candidate inhibitors for TMEM164, including activity for Montelukast S-enantiomer with 4 order of magnitude higher affinity. Our works not only demonstrates TMEM164 as a membrane lipid remodeler that controls the ferroptotic fate, but also highlights the power of integrating multi-scale platforms to unravel distinct mechanisms and functions.
- Open Access
- 7 December 2025
- Published by Springer Nature in npj Microgravity
- Vol. 12 (1)
Staphylococcal enterotoxin C2 rescued simulated microgravity-induced bone loss and the trans-differentiation of BMSCs into adipocytes
Exposure to microgravity decreases bone volume and increases marrow fat, partly due to impaired BMSC osteogenesis and enhanced adipogenesis. Staphylococcal enterotoxin C2 (SEC2) can influence BMSC differentiation, potentially promoting osteogenesis. This study investigated SEC2’s effects on bone loss and marrow fat in hindlimb suspension (HLS) mice and BMSC differentiation under simulated microgravity. Results showed SEC2 alleviated bone deterioration and reduced marrow adiposity, promoting osteogenic over adipogenic differentiation by activating ERK/β-catenin signaling pathways. SEC2 increased ERK phosphorylation and β-catenin nuclear translocation, with effects diminished upon β-catenin knockdown. These findings reveal a novel mechanism by which SEC2 modulates BMSC fate under microgravity, highlighting its potential as a therapeutic agent for preventing bone loss and marrow adiposity in microgravity conditions.
- 7 December 2025
- Published by Springer Nature in npj Microgravity
- Vol. 12 (1)
Open AccessStaphylococcal enterotoxin C2 rescued simulated microgravity-induced bone loss and the trans-differentiation of BMSCs into adipocytes
Exposure to microgravity decreases bone volume and increases marrow fat, partly due to impaired BMSC osteogenesis and enhanced adipogenesis. Staphylococcal enterotoxin C2 (SEC2) can influence BMSC differentiation, potentially promoting osteogenesis. This study investigated SEC2’s effects on bone loss and marrow fat in hindlimb suspension (HLS) mice and BMSC differentiation under simulated microgravity. Results showed SEC2 alleviated bone deterioration and reduced marrow adiposity, promoting osteogenic over adipogenic differentiation by activating ERK/β-catenin signaling pathways. SEC2 increased ERK phosphorylation and β-catenin nuclear translocation, with effects diminished upon β-catenin knockdown. These findings reveal a novel mechanism by which SEC2 modulates BMSC fate under microgravity, highlighting its potential as a therapeutic agent for preventing bone loss and marrow adiposity in microgravity conditions.
- Open Access
- 29 October 2025
- Published by Springer Nature in Research Square
Entorhinal cholecystokinin in Alzheimer’s disease: its earliest vulnerability and rescue effects across different disease stages
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline. The entorhinal cortex (Ent) is among the earliest affected regions, and its neuropeptide cholecystokinin (CCK) supports neocortical-associated memory. Although our previous work demonstrated that CCK treatment rescues cognition and neuroplasticity in aged AD mice, the correlations among CCK expression, synaptic function, and cognitive decline with aging remain poorly understood.Using 3xTg-AD mice (2–18 months), we performed stereological, histological, and molecular analyses to evaluate brain atrophy, neuronal loss, glial responses, and gene expression. Cognitive function was assessed using novel object recognition and rotarod tests, while synaptic integrity was measured via electrophysiological recordings. Importantly, we investigated the therapeutic potential of CCK-B receptor (CCK-BR) agonists on cognition and neuroplasticity across disease stages of AD.The Ent exhibits significant atrophy and excitatory neuronal loss as early as 7 months of age, confirming its role as one of the earliest and most severely affected regions in AD. CCK was downregulated earlier than other synaptic genes in the Ent and other brain regions. CCK-4 treatment rescued deficits in synaptic plasticity and cognition in 3xTg-AD mice across multiple disease stages. Long-term administration of HT-267, an optimized CCK-4 analogue, in young 3xTg-AD mice delayed cognitive decline, enhanced synaptic scaffolding, and restored long-term potentiation in both the cortex and hippocampus (HPC).Our findings identify CCK downregulation as an early biomarker in AD and demonstrate the therapeutic effects of CCK-BR agonists in mitigating cognitive and synaptic deficits from mild to severe disease stages. The ability of long-term CCK-4 analogue treatment to decelerate AD progression indicates its promise as an early intervention strategy.
- 29 October 2025
- Published by Springer Nature in Research Square
Open AccessEntorhinal cholecystokinin in Alzheimer’s disease: its earliest vulnerability and rescue effects across different disease stages
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline. The entorhinal cortex (Ent) is among the earliest affected regions, and its neuropeptide cholecystokinin (CCK) supports neocortical-associated memory. Although our previous work demonstrated that CCK treatment rescues cognition and neuroplasticity in aged AD mice, the correlations among CCK expression, synaptic function, and cognitive decline with aging remain poorly understood.Using 3xTg-AD mice (2–18 months), we performed stereological, histological, and molecular analyses to evaluate brain atrophy, neuronal loss, glial responses, and gene expression. Cognitive function was assessed using novel object recognition and rotarod tests, while synaptic integrity was measured via electrophysiological recordings. Importantly, we investigated the therapeutic potential of CCK-B receptor (CCK-BR) agonists on cognition and neuroplasticity across disease stages of AD.The Ent exhibits significant atrophy and excitatory neuronal loss as early as 7 months of age, confirming its role as one of the earliest and most severely affected regions in AD. CCK was downregulated earlier than other synaptic genes in the Ent and other brain regions. CCK-4 treatment rescued deficits in synaptic plasticity and cognition in 3xTg-AD mice across multiple disease stages. Long-term administration of HT-267, an optimized CCK-4 analogue, in young 3xTg-AD mice delayed cognitive decline, enhanced synaptic scaffolding, and restored long-term potentiation in both the cortex and hippocampus (HPC).Our findings identify CCK downregulation as an early biomarker in AD and demonstrate the therapeutic effects of CCK-BR agonists in mitigating cognitive and synaptic deficits from mild to severe disease stages. The ability of long-term CCK-4 analogue treatment to decelerate AD progression indicates its promise as an early intervention strategy.
- Open Access
- 12 September 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 328 (Pt 1) , 147650
DHA laden liposome incorporated HA-menthol-CD host-guest hydrogels as delivery system for osteoarthritis treatment
- 12 September 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 328 (Pt 1) , 147650
Open AccessDHA laden liposome incorporated HA-menthol-CD host-guest hydrogels as delivery system for osteoarthritis treatment